Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax^TM) after homologous and heterologous two-dose regimens.

ABSTRACT:

Objectives

To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax^TM) given as a third (booster) dose to individuals primed with different primary vaccine regimens.

Methods

A third dose was administered to individuals with an interval range of 3-10 months after the second dose. The four groups were classified according to their primary vaccine regimens, including two-dose BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell responses.

Results

Overall, 210 individuals were enrolled and boosted with the Covovax^TM vaccine. The reactogenicity was mild to moderate. Most participants elicited a high level of bindin

SUBMITTER: Kanokudom S 

PROVIDER: S-EPMC9678824 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature